In one of the first studies on the activity of the CDK4/6 inhibitor, palbociclib, Finn and colleagues demonstrated that luminal-type breast cancer cells expressing estrogen receptor, including luminal-type cells with HER2 amplification, were significantly more sensitive to palbociclib than basal-type ER-negative cells [41]. This evidence concerns the gene ESR1 and breast carcinoma.